Duchenne muscular dystrophy, a degenerative disease mostly affecting young boys, is one of the top targets for gene therapy developers. Recently, however, the pace of …
Biogen is searching for a new CEO along with additional ways to cut costs after another quarter of paltry sales for its closely watched Alzheimer’s …
By a slim margin, advisers to the Food and Drug Administration have concluded that the agency should hold off approving a closely watched, experimental medicine …
Dive Brief: Eli Lilly and Boehringer Ingelheim’s drug Jardiance kept clinical trial participants with kidney disease from needing dialysis or a transplant, the companies announced …
Dive Brief: Roche has outlined a new clinical path forward for a closely watched Huntington’s disease drug ten months after disappointing Phase 3 study results …
The biggest industry news of the week came not from the J.P. Morgan Healthcare Conference or any associated announcements, but from Washington, D.C, where the …
Novartis’ testing of canakinumab, which works by curbing inflammatory signaling in cells, for the seemingly unrelated use in lung cancer stems from an intriguing 2011 …
As the global response to COVID-19 continues to move from a state of national lockdowns to the re-opening of societies, diagnostic assay developers are confronting …
